Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Microencapsul ; 20(3): 317-27, 2003.
Article in English | MEDLINE | ID: mdl-12881113

ABSTRACT

Paclitaxel is a promising anti-cancer drug as well as a radiosensitizer for chemotherapy and radiotherapy applications. Because of the poor solubility of paclitaxel in water and most pharmaceutical reagents, it is usually formulated with an adjuvant called Cremophor EL, which causes severe side effects. This work develops new dosage forms of paclitaxel for controlled release application, which do not require the adjuvant and, thus, can avoid its associated side effects. Paclitaxel was encapsulated into the PLGA matrix with various additives such as polyethylene glycol (PEG), isopropyl myristate (IPM) and d-alpha tocopheryl polyethylene glycol (Vitamin E TPGS). These additives were used to enhance the release rate of paclitaxel from the polymer matrix. Spray-drying and an hydraulic press were used to prepare paclitaxel-PLGA microspheres and discs. The microspheres and discs were given different irradiation doses to investigate their effects on the surface morphology (characterized by SEM, AFM and XPS) and in vitro release properties. There seems to be a small effect of the ionizing radiation on various formulations. Although the irradiation did not cause observable changes on the morphology of the polymer matrix, the release rate can be enhanced by a few per cent. It was found that PEG has the highest enhancement effect for release rate among all the additives investigated in this study.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Gamma Rays , Lactic Acid/radiation effects , Paclitaxel/administration & dosage , Polyglycolic Acid/radiation effects , Polymers/radiation effects , Antineoplastic Agents, Phytogenic/pharmacokinetics , Biocompatible Materials , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Drug Carriers , Drug Compounding/methods , Humans , Lactic Acid/chemistry , Microscopy, Electron, Scanning , Microspheres , Molecular Weight , Paclitaxel/pharmacokinetics , Particle Size , Polyglycolic Acid/chemistry , Polylactic Acid-Polyglycolic Acid Copolymer , Polymers/chemistry , Radiation Dosage , Radiation-Sensitizing Agents/administration & dosage , Radiation-Sensitizing Agents/pharmacokinetics
2.
J Agric Food Chem ; 49(12): 5866-73, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11743776

ABSTRACT

This study focuses on the hydrolysis of terbufos, an organophosphorus pesticide. Combining GC-MS and wet chemistry methods, di-tert-butyl disulfide and formaldehyde were identified and quantified as major degradation products. Diethyl dithiophosphate was also indirectly identified as a degradation product under alkaline conditions. Hydrolysis rate constants of terbufos under homogeneous conditions were comparable to those of phorate and show relative insensitivity to pH under slightly acidic to neutral pH conditions, as the observed rate constants varied only in the range of (4.5-5.0) x 10(-6) s(-1) between pH 5.7 and 9.4; neutral hydrolysis is thus the most dominant hydrolysis pathway of terbufos in ambient waters. The mechanisms for terbufos hydrolysis and the formation of the major products and their temporal profiles are discussed. To assess the environmental impact of degradation products of this widely used pesticide, Microtox was used to analyze the toxicity of terbufos and two of its degradation products: diethyl dithiophosphate and di-tert-butyl disulfide; the EC(50) of terbufos was found to be >17 microM, whereas the EC(50) of di-tert-butyl disulfide was 1.3 microM.


Subject(s)
Insecticides/chemistry , Organothiophosphorus Compounds , Animals , Biological Assay , Chromatography, Gas , Daphnia/drug effects , Disulfides/analysis , Formaldehyde/analysis , Gas Chromatography-Mass Spectrometry , Hydrolysis , Insecticides/toxicity , Kinetics , Oncorhynchus mykiss
SELECTION OF CITATIONS
SEARCH DETAIL
...